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Abstract Uptake and intestinal metabolism of physiologically
active genistin were studied in an ex vivo intestinal perfusion
model; luminally applied concentrations were 5.9, 12.0, and 23.8
Wmol/l. The intestinal absorption of genistin was 14.9% ( þ 2.3,
n = 9), irrespective of the amounts applied. The majority of the
absorbed genistin appeared as genistein glucuronide (11.6%),
also recovered as the main metabolite on the luminal side
(19.5%). Minor amounts of genistin (1.3%) and genistein (1.9%)
were found on the vascular side, whereas 15.4% of applied
genistin was luminally cleaved to yield genistein. Sulfate
derivatives of genistein or genistin were not observed. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Iso£avones, major dietary components of soybeans [1],
have recently received great attention because of their pro-
posed health-related and clinical bene¢ts such as estrogen re-
ceptor binding [2] and natural killer cell activation [3]. There
have been numerous investigations regarding the antioxidative
and anticancerogenic activity of soy and its bioactive iso£a-
vones, the glycosides genistin and daidzin and the aglycones
genistein and daidzein [4^6].
Intestinal absorption of genistin (genistein-7-glucoside) is a
prerequisite for its proposed chemopreventive action. Avail-
able research on genistin absorption has chie£y been directed
to examinations of urinary, biliary and fecal excretion [7^10].
A recent study focused on the absorption of iso£avones in the
rat stomach [11]. While aglycones were absorbed from the rat
stomach, absorption of genistin has not been observed. The
aim of the present study was to evaluate absorption and me-
tabolism of genistin by using an isolated rat small intestine
(duodenum, jejunum and ileum) [12,13]. This organ perfusion
model facilitates direct investigation of luminal disappearance
and venous appearance of administered compounds, thereby
allowing the estimation of intestinal absorption.
2. Materials and methods
2.1. Animals
Male Sprague^Dawley rats (CD rats), 30 days old and weighing
about 130 g, were obtained from Charles River (Sulzfeld, Germany).
Rats were fed a cornstarch-based iso£avone-free synthetic diet (Altro-
min C-1000, Altromin International GmbH, Lage, Germany) for 14
days to allow elimination of iso£avones from the organism. Animals
were provided with free access to tap water and food. For perfusions
with genistin animals weighed 216.5 þ 17.2 g (n = 9) and for control
perfusions with basic luminal media 226.0 þ 11.1 g (n = 4).
2.2. Vascularly and luminally perfused rat small intestine
The small intestine was prepared in rats as described elsewhere [13^
16]. Luminal media consisted of 5.9, 12.0, or 23.8 Wmol/l genistin,
none in the case of controls, and 135 mmol/l NaCl, 20 mmol/l
NaHCO3 at pH 7.2.
Oxygen uptake and acid^base homeostasis (Clark pO2 electrode
and pH electrode integrated in an ABL 30 Acid^Base Analyzer; Ra-
diometer, Copenhagen, Denmark) were carefully controlled. Glucose,
lactate and pyruvate were determined photometrically using enzy-
matic test kits (Monotest; Boehringer Mannheim, Germany). For
glucose the MPR3 Glucose/GOD-Perid0 test kit (glucose oxidase,
peroxidase; ABTS0 ; Boehringer Mannheim, Germany), for lactate
the MPR3 lactate test kit (lactate dehydrogenase; NAD) and for
pyruvate the MPR1 pyruvate test kit (lactate dehydrogenase;
NADH) were used.
The study was approved by the Regierungspra«sidium Stuttgart,
Germany.
2.3. Sampling and sample preparation
Vascular (50 ml) and luminal (5 ml) aliquots were obtained and the
entire isolated small intestine as well as the associated blood vessels
were harvested for analyses of genistin, genistein and their conjugates
with reverse-phase high-performance liquid chromatography (HPLC)
with ultraviolet (UV) and mass spectrometry (MS) detection after
sample preparation as described below.
2.3.1. Vascular samples. Of each vascular sample, 2 ml was spiked
with internal standard 4-nitrophenol (50 Wl of a 170 Wmol/l solution)
and prepared as described earlier [15]. Genistin and genistein exhib-
ited a recovery of 100.1 þ 3.9% and 97.2 þ 3.0%, respectively
(means þ S.D.).
2.3.2. Luminal samples. As internal standard 4-nitrophenol (20 Wl
of a 23.5 mmol/l solution) was added to the luminal e¥uent of a
10 min period and prepared as described earlier [15]. Genistin and
genistein recovery was 100.3 þ 1.8% and 99.9 þ 1.2%, respectively
(means þ S.D.).
2.3.3. Small intestinal tissue and blood vessels. After lyophiliza-
tion, the tissue was powdered using a pestle and mortar, and defatted
by duplicate extraction with 10 ml hexane. The pellet was extracted
three times with 3 ml (1 ml in the case of blood vessels) methanol/
acetic acid (3%) (1:1) and centrifuged at 2800Ug for 20 min. The
extracts were pooled and the volume adjusted to 10 ml (3 ml in the
case of blood vessels). Genistin and genistein recovery was
100.4 þ 3.9% and 100.0 þ 4.8%, respectively (means þ S.D.) for small
intestinal tissue and 99.4 þ 4.4% and 96.4 þ 9.9%, respectively
(means þ S.D.) for blood vessels.
2.3.4. Clean-up for LC^MS identi¢cation of genistin and genistein
conjugates. Twelve milliliter of the vascular perfusate was prepared
as described earlier [16].
2.4. Analytical procedures
2.4.1. Gradient HPLC system with UV detection. The HPLC sys-
tem and the column used were previously described [15]. The eluents
were composed of 0.2% acetic acid in H2O (A) and 0.2% acetic acid in
acetonitrile (B). The elution conditions were as follows: 0^2 min 5%
B, 2^9 min 5^15% B, 9^20 min 15^60% B, 20^22 min 60^5% B. An
injection volume of 25 Wl genistin and genistein solution resulted in
detection limits of 11 nmol/l and 5 nmol/l and quantitation limits of
20 nmol/l and 9 nmol/l, respectively.
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2.4.2. Gradient HPLC system with MS detection (LC^MS). For
the identi¢cation of genistin and genistein conjugates we used a gra-
dient HPLC system as described earlier [16].
2.4.3. Cleavage of iso£avone conjugates. Genistin and genistein
conjugates were analyzed as genistein after enzymatic cleavage accord-
ing to Sfakianos et al. [17], with some modi¢cations as described
earlier [15].
2.5. Chemicals and solvents
All chemicals used were of analytical grade. Solvents for HPLC
analysis were of HPLC grade. Genistin was purchased from Extra-
synthese (Genay, France), genistein and the enzymes L-glucuronidase
and arylsulfatase from Sigma-Aldrich (Deisenhofen, Germany).
2.6. Calculations
Fluxes (nmol min31 (g dry intestine)31, means þ S.D.) were calcu-
lated from arterio-venous and proximo-distal concentration di¡eren-
ces (vC), respectively, the corresponding £ow rates and the dry weight
(DW) of the entire small intestine used in the experiment according to
the following equation:
Flux  vC nmol ml
31Uflow ml min31
DW g
Statistical di¡erences of £uxes were determined using ANOVA and
subsequent Tukey’s range test for paired observations at a procedure-
wise error rate of 5%. Viability parameters were compared using Stu-
dent’s t-test for unpaired observations. P values less than 0.05 were
considered to indicate signi¢cant di¡erences.
3. Results
In control perfusion experiments with genistin-free basic
perfusion media, neither genistin nor genistein was detected.
Genistin and genistein stability in the luminal and vascular
perfusate was con¢rmed for 10 h at 37‡C. Viability of the
organ preparation was con¢rmed in all perfusion experiments
by repeatedly measuring oxygen uptake, glucose^lactate han-
dling and acid^base homeostasis. No signi¢cant di¡erences in
viability data could be observed between genistin and control
perfusion experiments1.
Most of the luminally administered genistin left the organ
preparation via luminal e¥ux (Table 1). Main compounds in
the luminal e¥uent were genistin, followed by genistein and
genistein glucuronide. Genistein glucuronide was veri¢ed via
LC^MS by the molecular ion [M3H]3 at m/e 445 and the
signal for the aglycone fragment [M3glucuronic acid3H]3 as
base peak at m/e 269. 14.9% of genistin administered (mean of
all nine experiments) appeared on the vascular side, chie£y as
genistein glucuronide but also as genistein and as unmetabol-
ized genistin. Genistein glucuronide and genistin in the vascu-
lar e¥uent were also veri¢ed by LC^MS. Characteristic frag-
ment ions of genistin were the molecular ion [M3H]3 at m/e
431 and the aglycone ion [genistein3H]3 at m/e 269. Genis-
tein glucuronide was preferentially secreted to the luminal
side. Minute amounts of the administered genistin were lo-
cated in the intestinal tissue and the blood vessels as un-
changed genistin, genistein and genistein glucuronide.
Luminal disappearance and vascular appearance rates of
genistin as well as vascular and luminal appearance rates of
metabolites increased proportionally to increasing luminal
genistin concentrations applied (Table 2). Fig. 1 shows the
time dependence of the £uxes in experiments with 713.1
nmol genistin applied.
Table 1
Distribution of genistin, genistein and genistein glucuronide in the luminal, vascular and tissue compartments after perfusion experiments with
the isolated rat small intestine
Applied genistin 176.8 þ 1.8 360.1 þ 0.0 713.1 þ 3.6
nmol þ S.D. % þ S.D. nmol þ S.D. % þ S.D. nmol þ S.D. % þ S.D.
Luminal loss :
Genistin 70.9 þ 11.0 40.1 þ 6.0 209.8 þ 5.3 58.3 þ 1.5 306.6 þ 58.5 43.0 þ 8.0
Genistein 26.2 þ 7.9 14.9 þ 4.5 56.2 þ 5.0 15.6 þ 1.3 112.9 þ 33.7 15.8 þ 4.7
Glucuronide 42.9 þ 2.3 24.3 þ 1.1 46.3 þ 1.3 12.9 þ 0.4 151.2 þ 37.6 21.2 þ 5.4
Total 140.0 þ 10.3 79.3 þ 5.1 312.3 þ 1.1 86.8 þ 0.3 570.7 þ 52.0 80.0 þ 6.7
Vascular appearance
Genistin 2.5 þ 0.5 1.4 þ 0.3 5.9 þ 4.0 1.6 þ 1.1 6.1 þ 3.2 0.9 þ 0.4
Genistein 4.1 þ 0.8 2.3 þ 0.5 6.9 þ 4.3 1.9 þ 1.2 10.6 þ 2.4 1.5 þ 0.3
Glucuronide 18.9 þ 4.2 10.7 þ 2.6 33.3 þ 12.0 9.2 þ 3.3 105.9 þ 15.2 14.8 þ 2.2
Total 25.5 þ 3.3 14.4 þ 2.1 46.1 þ 7.7 12.7 þ 2.1 122.6 þ 17.6 17.2 þ 2.6
Intestinal tissue
Genistin 0.6 þ 0.6 0.3 þ 0.3 0.4 þ 0.0 0.1 þ 0.0 0.6 þ 0.1 0.1 þ 0.0
Genistein 3.2 þ 1.3 1.8 þ 0.7 3.4 þ 1.6 0.9 þ 0.4 5.5 þ 2.0 0.8 þ 0.3
Glucuronide 3.0 þ 1.9 1.7 þ 1.1 1.2 þ 0.8 0.3 þ 0.3 3.1 þ 0.9 0.5 þ 0.2
Total 6.8 þ 1.7 3.8 þ 1.0 5.0 þ 0.9 1.3 þ 0.3 9.2 þ 2.9 1.4 þ 0.4
Blood vessels
Genistin traces traces 0.08 þ 0.02 0.02 þ 0.01 0.06 þ 0.00 0.01 þ 0.01
Genistein 0.05 þ 0.03 0.03 þ 0.01 0.09 þ 0.02 0.03 þ 0.01 0.08 þ 0.05 0.01 þ 0.01
Glucuronide 0.53 þ 0.28 0.30 þ 0.16 0.13 þ 0.02 0.04 þ 0.01 0.73 þ 0.24 0.10 þ 0.03
Total 0.58 þ 0.28 0.33 þ 0.17 0.30 þ 0.04 0.09 þ 0.01 0.87 þ 0.26 0.12 þ 0.04
Recovery 172.9 þ 8.1 97.8 þ 3.6 363.7 þ 8.4 100.9 þ 2.3 703.4 þ 31.9 98.7 þ 3.9
Concentrations of 5.9, 12.0, and 23.8 Wmol/l were applied, each in three experiments, corresponding to genistin amounts of 176.8, 360.1, and
713.1 nmol, respectively. ‘Traces’ are under the quantitation limit.
1 Viability parameters (means þ S.D.): control perfusion (n = 4) and
genistin (n = 9) experiments: oxygen consumption: 3.8 þ 0.3 (5.0 þ 0.6)
Wmol min31 g31, lactate^pyruvate ratio: 27.4 þ 5.3 (30.8 þ 5.0) ; glu-
cose consumption: 6.9 þ 1.5 (6.0 þ 1.6) Wmol min31 g31 ; arterial pres-
sure 79.5 þ 21.0 (74.8 þ 12.1) mm Hg; arterial pH: 7.5 þ 0.1 (7.5 þ 0.0) ;
venous pH: 7.3 þ 0.0 (7.4 þ 0.0).
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In none of the luminal and vascular perfusates or gut tissue
extracts were mixed glucurono^sulfoconjugates, sulfate conju-
gates of genistein and glucuronide or sulfate conjugates of
genistin detectable with LC^MS.
4. Discussion
To assess the intestinal absorption and metabolism of gen-
istin, we used an isolated preparation of a vascularly and
luminally perfused rat small intestine, characterized by fully
maintained tissue viability. Intact mucosal morphology with-
out loss of villous tip cells after 120 min perfusion has pre-
viously been demonstrated in histologic specimens of the iso-
lated intestinal preparations perfused in the same way as in
the present study [18]. As in earlier studies, viability and func-
tional integrity of the intestinal preparation were carefully and
continuously controlled [13,14]. The functional integrity of the
intestinal preparation was monitored and the viability con-
¢rmed in agreement with data from earlier studies using the
same model [15,16].
Control perfusions with basic media without genistin con-
¢rmed that the small intestine of the experimental animals did
not contain genistin sequestered from food. It must also be
emphasized that in the present study the administered amount
of genistin (176.8^713.1 nmol) was in the physiological range
corresponding well to its usual nutritional intake with food
(1^4 g from tofu or 1.5^6 g from tempeh [1]).
The absorption rate of total genistein compounds of about
15% is in good agreement with earlier observations gained
from human feeding experiments with soymilk corresponding
to 14.6% [19], 10% and 37% [8], respectively. In feeding ex-
periments with rats, bioavailability of genistin calculated from
the urinary excretion of genistein and genistein derivatives was
about 22% [20], indicating that other parts of the digestive
tract might be involved in the absorption processes.
The ability of mammals to hydrolyze £avonoid and iso£a-
vonoid glycosides to the corresponding aglycones has been
repeatedly claimed [21^23]. Microorganisms of the rat and
human intestine are able to cleave L-glucosides [24]. However,
since genistin remains stable in the luminal e¥uent, a micro-
bial cleavage to genistein during perfusion is unlikely and
genistein appearing luminally was more likely hydrolyzed in
the small intestinal tissue and subsequently secreted.
It was proposed that £avonoid glycosides are hydrolyzed to
the corresponding less polar aglycones prior to gastrointesti-
nal absorption [25^27]. In the present study, however, genistin
was partly absorbed without previous cleavage which contra-
dicts the above assumption. Supporting our observation,
phloretin and quercetin have recently been shown to occur
as glycosides in human plasma [28].
Transepithelial transport of naphthol and 4-nitrophenol
monoglucoside conjugates by the sodium-dependent glucose
transporter SGLT1 was con¢rmed in experiments with everted
intestinal sac preparations [29,30]. From human studies it was
concluded that quercetin absorption is enhanced by conjuga-
tion with glucose, possibly by absorption via the glucose car-
rier [31]. Genistin, as genistein-7-monoglucoside, might also
be absorbed by this transport system. Yet, the absorption
rate of genistein [15] was not enhanced due to conjugation
Table 2
The average £uxes of genistin and its metabolites over the perfusion time of 60 min (nmol min31 g31, means þ S.D.)
Applied genistin (nmol þ S.D.) 176.8 þ 1.8 360.1 þ 0.0 713.1 þ 3.6
Luminal disappearance 2.0 þ 0.1 3.2 þ 0.3 8.4 þ 1.0
Luminal appearance (secretion) 0.9 þ 0.3 2.1 þ 0.3 5.3 þ 0.3
Vascular appearance 0.5 þ 0.0 0.9 þ 0.1 2.5 þ 0.3
Fig. 1. Fluxes (nmol min31 g31, means þ S.D.) of genistin and genis-
tin metabolites in the perfused rat small intestine. A concentration
of 23.8 Wmol/l, corresponding to a genistin amount of 713.1 nmol,
was applied in three perfusion experiments each of 60 min. Luminal
and vascular perfusates were pooled every 10 min and analyzed for
genistin and its conjugates. A: Luminal disappearance rate of genis-
tin. B: Vascular appearance rates of genistin, genistein and genistein
glucuronide (gray, white and hatched bars, respectively). C: Lumi-
nal appearance rate of genistein and genistein glucuronide (gray and
white bars, respectively) (back transport).
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with glucose. An increase in luminal genistin disappearance
rates was seen in proportion to the concentrations applied
luminally, thus rendering a transepithelial transport of genis-
tin by di¡usion more likely than an active transport by a
carrier system.
Regardless of the concentrations applied we observed an
e⁄cient cleavage of genistin to genistein and a conjugation
of the aglycone with glucuronic acid (Table 1). Several inves-
tigators have shown this phase II biotransformation to occur
in the gut tissue [30,32,33]. Genistein glucuronide was prefer-
entially secreted into the luminal perfusate, while only about a
third was transported to the vascular side. The highly hydro-
philic, charged glucuronides (pKa = 2^3, [34]) are unlikely to
pass cell membranes by passive di¡usion, however, specialized
transport carrier systems for phenol glucuronides in the brush
border and the basolateral membrane may explain our obser-
vations [32,35].
Genistein glucuronides were reported to be weakly estro-
genic and are activators of human natural killer cells at nutri-
tionally relevant concentrations [3]. In experiments with
everted rat intestine, it was recently shown that secreted glu-
curonides are reabsorbed in the colon, and thus, not lost to
the organism [36].
The implication of the intestinal model as presented facili-
tates direct ex vivo investigations of intestinal handling of
phytochemicals, thereby allowing future research on their ab-
sorption, transport, distribution and metabolism.
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